Market closed
Instil Bio/$TIL
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Instil Bio
Instil Bio Inc is a clinical-stage biopharmaceutical company focused on developing a cell therapy pipeline of autologous tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer. It is also engaged in developing a novel class of genetically engineered TIL therapies using its Co-Stimulatory Antigen Receptor, or CoStAR, platform. Its pipeline includes ITIL-306 which expresses a CoStAR molecule designed to recognize FRα, a tumor-associated antigen that is expressed on numerous solid tumors, including ovarian cancer, uterine cancer, NSCLC, and renal cancer.
Ticker
$TIL
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
49
Website
Instil Bio Metrics
BasicAdvanced
$172M
-
-$11.56
1.74
-
Price and volume
Market cap
$172M
Beta
1.74
52-week high
$67.36
52-week low
$9.62
Average daily volume
100K
Financial strength
Current ratio
12.896
Quick ratio
11.784
Long term debt to equity
47.401
Total debt to equity
48.4
Interest coverage (TTM)
-7.63%
Management effectiveness
Return on assets (TTM)
-12.40%
Return on equity (TTM)
-36.63%
Valuation
Price to book
0.97
Price to tangible book (TTM)
0.97
Price to free cash flow (TTM)
-2.922
Growth
Earnings per share change (TTM)
-61.87%
3-year earnings per share growth (CAGR)
-27.58%
What the Analysts think about Instil Bio
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Instil Bio stock.
Instil Bio Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
Instil Bio Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Instil Bio News
AllArticlesVideos
Instil Bio Announces Clinical Progress in China for IMM2510/SYN-2510, a Clinical-Stage PD-L1xVEGF Bispecific Antibody
GlobeNewsWire·2 weeks ago
Bullish Outlook On Instil Bio's Investigational Cancer Drug: Jefferies Sees Over 300% Stock Upside
Benzinga·3 weeks ago
Instil Bio's Strategic Shift To SYN-2510: A Speculative 'Buy' Opportunity
Seeking Alpha·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Instil Bio stock?
Instil Bio (TIL) has a market cap of $172M as of January 31, 2025.
What is the P/E ratio for Instil Bio stock?
The price to earnings (P/E) ratio for Instil Bio (TIL) stock is 0 as of January 31, 2025.
Does Instil Bio stock pay dividends?
No, Instil Bio (TIL) stock does not pay dividends to its shareholders as of January 31, 2025.
When is the next Instil Bio dividend payment date?
Instil Bio (TIL) stock does not pay dividends to its shareholders.
What is the beta indicator for Instil Bio?
Instil Bio (TIL) has a beta rating of 1.74. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.